Affiliation:
1. Division of Infectious Diseases, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
2. Department of Laboratory Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
Abstract
ABSTRACT
With the increasing use of carbapenems, carbapenem-resistant Gram-negative bacteria have become a major concern in health care-associated infections. The present study was performed to evaluate the clinical and microbiological features of breakthrough Gram-negative bacteremia (GNB) during carbapenem therapy and to assess risk factors for development of breakthrough GNB. A case-control study was performed at a tertiary hospital from 2005 to 2014. Case patients were defined as individuals whose blood cultures grew Gram-negative bacteria while the patients were receiving carbapenems for at least 48 h before breakthrough GNB. Age-, sex-, and date-matched controls were selected from patients who received carbapenem for at least 48 h and did not develop breakthrough GNB during carbapenem treatment. A total of 101 cases of breakthrough GNB were identified and compared to 100 controls. The causative microorganisms for breakthrough GNB were
Stenotrophomonas maltophilia
(
n
= 33),
Acinetobacter baumannii
(
n
= 32),
Pseudomonas aeruginosa
(
n
= 21), and others (
n
= 15). Approximately 90% of
S. maltophilia
isolates were susceptible to levofloxacin and trimethoprim-sulfamethoxazole. The most common infection types were primary bacteremia (38.6%) and respiratory infections (35.6%). More than half of the patients died within a week after bacteremia, and the 30-day mortality rate was 70.3%. In a multivariate analysis, a longer hospital stay, hematologic malignancy, persistent neutropenia, immunosuppressant use, and previous colonization by causative microorganisms were significantly associated with breakthrough GNB. Our data suggest that
S. maltophilia
,
A. baumannii
, and
P. aeruginosa
are the major pathogens of breakthrough GNB during carbapenem therapy, in association with a longer hospital stay, hematologic malignancy, persistent neutropenia, immunosuppressant use, and previous colonization.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference31 articles.
1. Risk factors for carbapenem-resistant Gram-negative bacteremia in intensive care unit patients
2. Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum
3. CDC. 2013. Antibiotic resistance threats in the United States, 2013. CDC, Atlanta, GA.
4. Korean Nosocomial Infections Surveillance System, intensive care unit module report: data summary from July 2009 through June 2010;Kwak YG;Korean J Nosocomial Infect Control,2011
5. Simultaneous antibiotic levels in “breakthrough” gram-negative rod bacteremia
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献